Albendazole oral emulsion is a national new drug for the treatment of hydatid disease, which was put on the market by Shaanxi Hanjiang Pharmaceutical Group co.,Ltd. It is a national patent protected drug with the approval number: H20050961. The drug was developed by Shaanxi Hanjiang Pharmaceutical Group co.,Ltd. Chinese Center for Disease Control and Prevention (CDC), Xinjiang Uygur Autonomous Region Center for Disease Controland Prevention, Hydatid disease Prevention Institute of Ministry of Health. Albendazole oral emulsion is produced by Shaanxi Hanwang Pharmaceutical Co., Ltd. an authorized holding company of Shaanxi Hanjiang Pharmaceutical Group Co., Ltd. and Shaanxi Hanjiang Pharmaceutical Group Co., Ltd. owns the intellectual property rights of the drug.

Albendazole oral emulsion has gained positively recognition by the majority of patients for its good therapeutic effect since its launch. At present, the drug has been recommended by the Ministry of Health as the first selected drug for the treatment of hydatid disease. After more than ten years of clinical application,quality effect is remarkable. The cure rate is up to 95.5%. Compared with albendazole tablets and albendazole capsules, the prevention rate is increasedby 30-40%. The current sales area coverage: Xinjiang Uygur Autonomous Region,Tibet Autonomous Region, Qinghai Province, Gansu Province, Inner Mongolia Autonomous Region, Ningxia Hui Autonomous Region, Sichuan Province and other regions.